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Clostridium difficile is a leading causative agent of hospital-acquired and community-acquired 
diarrhea in human. This study aims to characterize the predominant C. difficile strains, RT001 and 
126, circulating in Iranian hospitals in relation to resistant phenotypes, the antibiotic resistance 
genes, and their genetic relatedness. A total number of 735 faecal specimens were collected from 
patients suspected of CDI in Tehran hospitals. Typing and subtyping of the strains were performed 
using CE-PCR ribotyping and MLVA, respectively, followed by PCR assays for ARGs and indicators of 
Tns. Minimum inhibitory concentrations (MICs) of five antibiotics were determined by MIC Test Strips. 
Among 65 strains recovered from CDI patients, RT001 (32.3%) and RT126 (9.2%) were found as the 
most frequent ribotypes, and 64 MLVA types were identified. Using MLVA, RT001 and RT126 were 
subtyped into 6 and 4 groups, respectively. The vanA, nim, tetM, gyrA, gyrB genes were detected 
in 24.6%, 0%, 89.2%, 95.3%, and 92.3% of the strains, respectively. The indicators of Tns including 
vanHAX, tndX, and int were found in 0%, 3% and 29.2% of the strains, respectively. The most common 
amino acid (AA) alterations of GyrA and GyrB were related to substitutions of Thr82 → Val and 
Ser366 → Val, respectively. Resistance rate to metronidazole, vancomycin, tetracycline, ciprofloxacin, 
and moxifloxacin was 81.5%, 30.7%, 85%, 79%, and 74%, respectively. This study, for the first time 
revealed the subtypes of circulating RT001 and RT126 in Iran. It is of importance that the majority of the 
strains belonging to RT001 were multidrug resistant (MDR). This study also pointed to the intra-hospital 
dissemination of the strains belonging to RT001 and RT126 for short and long periods, respectively, 
using MLVA. The most important resistance phenotypes observed in this study was vancomycin-
resistant phenotypes. Resistance to metronidazole was also high and highlights the need to determine 
its resistance mechanisms in the future studies.
Clostridium difficile is a leading causative agent of hospital-acquired (HA) and community-acquired (CA) diarrhea 
in human1. Severe C. difficile infections (CDIs) are commonly associated with hypervirulent strains pertaining to 
PCR ribotypes (RTs) 027 and 078. The C. difficile RT001 is regarded to be a hypervirulent strain as well as RT0782. 
C. difficile RT126 is considered as a hypervirulent strain that is genetically close to RT078 (identical patterns of 
PCR ribotyping)3,4. The RT078 is one of the most common types of C. difficile isolated from human in Europe2,3. 
The RT001 and RT072 associated with lethal CDI, are common in Europe5,6. The RTs001/072 have almost identical 
patterns of PCR ribotyping and could be differentiated by multilocus variable-number tandem repeat analysis 
(MLVA)7. Capillary electrophoresis (CE)-PCR ribotyping is currently employed as an appropriate alternative to 
agarose gel-based PCR ribotyping for epidemiological surveillance. However, it needs to be combined with MLVA 
in order to subtype the strains with identical patterns, and determine the genetic relatedness of the strains3,8.
Oral vancomycin and metronidazole are the most commonly used antibiotics for treatment of CDI2,9. Reduced 
susceptibility to vancomycin C. difficile strains has been increased within the recent decade10. Mechanisms of 
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resistance to metronidazole have also remained elusive in C. difficile10. Several genes including vanA11, rpoC12, 
and murG12 are proposed to play a role in vancomycin resistance in C. difficile; however, resistance to vancomycin 
due to vanA could be of major concern as its horizontal transfer is likely to occur by Tn154613. The high level of 
resistance to fluoroquinolones (mainly associated with amino acid substitutions in GyrA and/or GyrB10) has also 
been demonstrated in hypervirulent strains14. Tetracyclines are less likely to be linked to the induction of CDI; 
however, the tetracycline-resistant strains of C. difficile are clinically important. These strains may carry the tetra-
cycline resistance genes (such as tetM and tetW genes) on the mobile genetic elements such as transposons (Tn) 
(i.e., Tn916, Tn5397, Tn6190, and Tn6235) possessing the ability of transferring genes inter- and intra-species10,15.
This study aims to characterize the predominant C. difficile hypervirulent strains, RT001 and 126, circu-
lating in Iranian hospitals in relation to resistant phenotypes, the antibiotic resistance genes, and their genetic 
relatedness.
Results
2-1- C. difficile strains. Out of 735 faecal specimens from cases suspected of CDI, 65 (8.8%) were positive 
for C. difficile by culture, L-prolin aminopeptidase test, and PCR for 16S rRNA gene. Of 65 strains, 8 (12.3%) were 
tcdA and tcdB negative and 57 strains (87.7%) were positive.
2-2- Antimicrobial susceptibility. Minimum inhibitory concentration (MIC) ranges were 0.125-256 mg/L, 
0.032–256 mg/L, 0.023–256 mg/L, 0.047–32 mg/L, and 0.023–256 mg/L for vancomycin, metronidazole, tetracy-
cline, ciprofloxacin, and moxifloxacin, respectively. Thirty percent (n = 20) of the strains were resistant to van-
comycin. Resistance to metronidazole, tetracycline, ciprofloxacin, and moxifloxacin was 81.5% (n = 53), 84.6% 
(n = 55), 78.4% (n = 51), and 73.8% (n = 48), respectively. MIC50 and 90 were the same for metronidazole 
(≥256 mg/L), ciprofloxacin (≥32 mg/L), and moxifloxacin (≥32 mg/L) against strains belonging to RT001. In 
RT001, MIC50 and 90 of vancomycin were 1.5 and ≥256 mg/L and MIC50 and 90 of tetracycline were 32 and 
≥256 mg/L. In RT126 strains, the MIC50 and 90 were as shown in Table 1.
2-3- Antibiotic resistance genes. PCR assay for vanA was positive in 81.2% (13/16) of the 
vancomycin- resistant strains examined (Supplementary Table File). Nucleotide variation in vanA gene was 
Cytosine680 → Thymine (C680 → T). vanHAX as marker of Tn1546 was not detected among the strains; there-
fore, absence of Tn1546 was confirmed. No strain was positive for nim gene. The gyrA gene was detected in 95% 
of strains using the primer set gyrA1- gyrA2. Of them, 32.2% and 4.8% were found with amino acid (AA) substi-
tution of Thr82 → Val and Thr82 → Ile, respectively. Using the gyrB1- gyrB2 primers, gyrB gene was detected in 
92% of strains which possessed one of the following AA substitutions: Ser366 → Val (6.6%), Ser416 → Ala (6.6%), 
Ser366 → Ala (6.6%), Asp426 → Asn (3.3%), and Asp426 → Val (1.6%). PCR assay for tetM was positive in 86.2% 
(50/58) of the tetracycline- resistant strains. Twenty-seven and six percent and 3% of the strains contained the 
int and tndX genes as markers of Tn916-like and Tn5397-like, respectively. The presence of presumed antibiotic 
resistance genes in relation to the RTs is shown in Table 2. Odds ratio (OR) and P value were calculated for all 
resistance genes, and also mutation in gyrA/B genes in relation to resistance to the antibiotics. For some variables, 
OR was not applicable (NA), since at least one of the values was zero (Table 2).
The nucleotide sequences of vanA gene, gyrA and gyrB were deposited in GenBank under the accession num-
bers as indicated in Supplementary Table File.
2-4- PCR ribotypes. Of the 65 strains examined, 56 strains were assigned to 22 known RTs including RT001 
(32.3%), RT002 (4.6%), RT003 (3.1%), RT005 (1.5%), RT014 (3.1%), RT023 (1.5%), RT029 (4.6%), RT037 (1.5%), 
RT038 (1.5%), RT039 (1.5%), RT060 (1.5%), RT072 (3.1%), RT084 (1.5%), RT097 (1.5%), RT126 (9.2%), RT131 
(1.5%), RT266 (3.1%), RT282 (1.5%), RT369 (1.5%), RT688 (3.1%), RT700 (1.5%), and RT139 (1.5%). The 
remaining 9 strains (6.6%) not found in two database (Clostridium difficile Network for England and Northern 
Ireland (CDRN) and National Reference Laboratory for Clostridium difficile at University Medical Centre, Leiden) 
were designated as “unidentified RTs”. Two of 9 strains had the same chromatograms files (PC091 and PC091b). 
The chromatograms files of the unidentified RTs are presented in Supplementary Figure File. RT for each strain 
is indicated in Supplementary Table File. The non- toxigenic strains (PC048, PC073, PC075, PC080, PC091, 
PC091b, PC102, and PC141) belonged to RT038, RT084, RT060, RT102, and unidentified RTs (Supplementary 
Table File). The strains of RT001 were isolated from patients in different hospitals including H3, H4, H9 and H6. 
In terms of ward of admission in each hospital for strains belonging to RT001, the following are noted: (i) two 
strains (PC114 and PC115) from H3 were found in different wards “Nose Ear Trachea (NET) and Intensive Care 
Unit (ICU)” with two months interval (November and December 2016); (ii) two strains (PC054 and PC056) from 




Vancomycin 0.5–2 0.875 2
Metronidazole 0.19–≥256 0.625 ≥256
Ciprofloxacin 0.25–≥32 ≥32 ≥32
Moxifloxacin 0.5–≥32 16.5 ≥32
Tetracycline 1.5–≥32 4 ≥32
Table 1. The MIC50 and 90 of antibiotics tested in C. difficile belonging to ribotypes 126.
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and “nephrology”; (iii) two strains (PC132 and PC133) from H9 were isolated from different wards including 
“infectious disease” and “surgery 2” with two months interval (May and June 2017) (Fig. 1b, Supplementary Table 
File). Regarding RT126, three strains (PC062, PC096, and PC106) were isolated from patients admitted to the 
ward “medical 2” in hospital H4 within different months (Fig. 1b, Supplementary Table File).
2-5- MLVA types. Using MLVA, subtyping of the 65C. difficile strains with different RTs patterns revealed 64 
MLVA types (Supplementary Table File) and 6 clonal complexes (CC1, CC2, CC3, CC4, CC5, and CC6) for RTs 
001, 072, 126, 060, and unidentified RTs. Each of four CCs; for example, CC2 (RT126), CC3 (unidentified RT), 
CC4 (RT126), and CC5 (RT001) were made up of a single RT; while two other CCs including CC1 and CC6 con-
tained different RTs. In other words, genetic relatedness (defined as single locus variant) was observed between 
RTs 001 and 072 in CC1, and also between RTs 001 and 60 in CC6. The CC1 as the largest CC included twelve 
RT001 and two RT072. In addition, two strains (PC114 and PC115) had identical MLVA types in CC1 (MLVA 
type 12) in all five loci (Supplementary Table File). The CC2 and CC4 included four out of six strains with RT126 
pattern (Fig. 1a), while the CC2 possessed two isolates (PC002 and PC010) from H3 hospital and outpatient in 
August and September 2014 (Fig. 1b, Supplementary Table File). The CC3 contained two isolates (PC091 and 
PC091b) with the same RT pattern (unidentified RT) from the same ward (“respiratory disease”) of H4 hospital. 
Also, the CC4 included two isolates (PC062 and PC096) from the “medical 2” ward of H4 hospital during three 
months (from August to October 2016) (Fig. 1b, Supplementary Table File).
The CDR4, CDR5, and CDR9 did not generate any amplicon in 6 isolates with RT126 and one isolate with 
RT668) and were considered to be absent or null (Supplementary Table File). Locus CDR4 with DI = 0.945 was 
found to be the most variable among the loci, whereas the locus CDR48 with DI = 0.651 had the lowest variabil-
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RT002 0 vs 1 0 vs 0 0 vs 3 0 vs 0 0 vs 0 0 vs 0 0 vs 0
RT003 0 0 vs 0 1 vs 1 0 vs 0 0 vs 0 0 vs 0 0 vs 0
RT005 1 vs 0 0 vs 0 0 vs 1 0 vs 0 0 vs 0 0 vs 0 0 vs 0
RT014 1 vs 0 0 vs 0 1 vs 1 0 vs 0 0 vs 0 0 vs 0 0 vs 0
RT023 0 vs 0 0 vs 0 0 vs 1 0 vs 0 0 vs 0 0 vs 0 0 vs 0
RT029 0 vs 1 0 vs 0 0 vs 1 0 vs 0 0 vs 0 0 vs 0 0 vs 0
RT037 0 vs 0 0 vs 0 1 vs 0 0 vs 0 0 vs 0 0 vs 0 0 vs 0
RT038 0 vs 0 0 vs 0 0 vs 1 Thr82Ile:0 vs 1
Thr82Ile:
0 vs 1 0 vs 0 0 vs 0
RT039 0 vs 0 0 vs 0 0 vs 1 0 vs 0 0 vs 0 0 vs 0 0 vs 0
RT060 0 vs 0 0 vs 0 0 vs 1 0 vs 0 0 vs 0 Ser366Ala:0 vs 1
Ser366Ala:
0 vs 1
RT072 0 vs 2 0 vs 0 0 vs 2 Thr82Val:1 vs 0
Thr82Val:
1 vs 0 0 vs 0 0 vs 0
RT084 0 vs 0 0 vs 0 0 vs 1 Thr82Ile:0 vs 1
Thr82Ile:
0 vs 1 0 vs 0 0 vs 0
RT097 0 vs 0 0 vs 0 0 vs 1 0 vs 0 0 vs 0 0 vs 0 0 vs 0
RT131 0 vs 1 0 vs 0 0 vs 1 0 vs 0 0 vs 0 0 vs 0 0 vs 0
RT266 0 vs 0 0 vs 0 1 vs 1 0 vs 0 0 vs 0 0 vs 0 0 vs 0
RT282 0 vs 1 0 vs 0 0 vs 1 0 vs 0 0 vs 0 0 vs 0 0 vs 0
RT389 0 vs 0 0 vs 0 0 vs 1 0 vs 0 0 vs 0 Ser366Ala/Asp426Val:0 vs 1
Ser366Ala/Asp426Val:
1 vs 0
RT688 1 vs 0 0 vs 0 0 vs 2 0 vs 0 0 vs 0 0 vs 0 0 vs 0
RT700 0 vs 0 0 vs 0 0 vs 1 0 vs 0 0 vs 0 0 vs 0 0 vs 0
RT139 0 vs 0 0 vs 0 0 vs 1 0 vs 0 0 vs 0 0 vs 0 0 vs 0
Total 3 vs 12 0 vs 0 7vs 42 4 vs 17 2 vs 19 1 vs 6 3 vs 4
Table 2. Presumed antibiotic resistance genes in relation to each PCR ribotype. aP value = 0.000. bOdds Ratio 
(OR) with 95% confidence interval = 1.0, P value = 0.950. cOdds Ratio (OR) with 95% confidence interval = 2.5, 
P value = 0.496. dOdds Ratio (OR) with 95% confidence interval = 8.5, P value = 0.129.
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Discussion
The CDI is a major medical threat to human health around the world. Most of the CDI cases reported recently 
in Europe are often associated with the hypervirulent strains such as RT027 and RT0787. Also, some of the C. 
difficile RTs such as RT001 are more likely to cause the severe CDI1. Accurate typing of C. difficile strains is 
crucial for defining whether a strain is sporadic or part of an outbreak. A study from Tehran, conducted on the 
isolates collected in 2011, showed that RT001 and RT126 are the most predominant RTs among the isolates of 
C. difficile16. The findings of the current study are consistent with those of the previous study by Azimirad et al., 
revealing that RT126 and RT001 are the most predominant RTs among C. difficile isolates16. In the current study, 
the faecal specimens were from patients while Azimirad et al., (2017), examined stool samples from hospitalized 
patients and swabs from environment as well as medical devices. Moreover, samples in their study were collected 
during 2011, whereas samples in our study were collected from 2011 to 2017. Also, an important point is that the 
subtyping of the isolates of different ribotypes by MLVA and the identification of resistance genes and transposons 
were performed for the first time in Iran. None of them have been carried out in Azimirad et al., study. Finding 
other different RTs in metropolitan Tehran might be arising from the difference in sample sizes, time periods and/
or target hospitals. The European studies emphasized that RT001 is one of the RTs that are frequently recovered 
from patients7. The association between RT001 and the severe CDI has been reported5, which may be related to 
high-density of spore production by C. difficile RT00117. In this research, the severity of CDI in patients has not 
been recorded; thus, assessment of such an association was not possible. Here, we applied the CE-PCR ribotyping 
as a robust method for typing and identifying the predominant RTs of C. difficile strains circulating in Tehran 
during 2011–2017. Afterwards, MLVA was performed to determine the genetic relatedness of the C. difficile RTs. 
Moreover, the antibiotic-resistant phenotypes of the predominant C. difficile RTs and their antibiotic resistance 
genes were identified.
In this study, the CE-PCR ribotyping of C. difficile strains demonstrated the RT001 as the most prevalent 
RT, followed by RT126 as the second most prevalent RT among C. difficile strains from target hospitals. The 
RT001 and RT126 were distributed in different CCs based on MLVA. In the Middle East, the hypervirulent strains 
RT027, RT078, RT001 and also RT126 were not found as the most prevalent RT, while one of the most common 
RT in Qatar, Kuwait, and Lebanon were RT258, RT139, and RT014, respectively. RT078 has not been found in 
those studies, but RT027 has been found in 1.3% and 0.9% of isolates in Qatar and Lebanon, respectively18–20. 
Based on the observed allelic diversity, CDR4 with DI = 0.945 had the most discriminatory power of the loci 
tested; a finding that is consistent with a previous report by Marsh et al.21.
Interestingly, the majority of strains with RT001 pattern (90.4%) were resistant to metronidazole. Previous 
studies in Europe reported a reduced susceptibility to metronidazole in 2008 and 201222,23. Of 21 strains belong-
ing to RT001, 7 strains were resistant to vancomycin (MICs of 4 strains =≥ 256 mg/L, MIC of one strain = 4 mg/L, 
MIC of one strain = 6 mg/L). In this work, the majority of the strains belonging to RT001 were multidrug resistant 
(MDR), defined as resistance to at least 4 antibiotics including vancomycin, metronidazole, ciprofloxacin, moxi-
floxacin, and tetracycline. Resistance to fluoroquinolones in RT001 was also reported by Krutova et al., in Czech 
Republic1. As already reported, RT001 and RT072 are considered as one complex (RT001/072). Here, we noted 
that the RT001 and RT072 had close genetic relatedness and clustered in CC1; although, they were obtained from 
Figure 1. Minimum spanning tree representation (MST) based on Multiple-Locus Variable Number Tandem 
Repeat Analysis (MLVA) for C. difficile strains. The numbers in the circles represent code of strain. If more 
than one number is present in one circle, it represents the strains with 100% similarity in five variable-number 
tandem repeat (VNTR) loci. The CCs represent six clonal complexes with a single locus variant. (A) The colored 
circles indicate ribotypes (RTs) of C. difficile strains. (B) The colored circles indicate the isolation sources of C. 
difficile strains.
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different hospitals (H3 and H9) (Fig. 1b). The genetic relatedness of RT001 and RT072 is also demonstrated pre-
viously in Europe7. More than half of the strains with RT001 pattern (57.1%) were located in CC1, even though 
they were obtained from the patients admitted to different hospitals (H3, H4, H9) or outpatients. The remaining 
strains belonging to RT001 were assigned to other CCs. Between November and December 2016, the strains 
belonging to RT001 including PC114 and PC115 were isolated from the same hospital (H3) in different wards. 
In August 2015, the strains PC054 and PC056 were isolated from the same hospital (H4) from different wards. 
Moreover, between May and June 2017, the strains PC132 and PC133 were isolated from the same hospital (H9) 
in different wards. The close genetic relatedness of the strains including PC114, PC115, PC132, and PC133 was 
also observed and confirmed by MLVA method (located in CC1 with difference in one locus). It is necessary to 
mention that RT001 was subtyped in different CCs, therefore; MLVA could subtype the identical RTs as it has 
already been found by Krehelova et al., in Slovakia24. It is important to remind that PC114 and PC115 had an 
identical MLVA type and were assigned in CC1; one may conclude that both strains have probably had a common 
ancestor. Antibiotic resistance pattern was similar in both strains except for fluoroquinolones. Although both 
strains were resistant to tetracycline, but with different MICs (PC114: MIC = 12 mg/L, PC115: MIC ≥ 256 mg/L), 
tetM gene was only found in one strain. It seems that different mechanisms might be implicated in the resistance 
to tetracycline in both strains.
In the current study, the RT126 was found as the second most prevalent RT among the C. difficile strains exam-
ined. All strains with RT126 pattern were susceptible to vancomycin and resistant to tetracycline. However, five of 
the six strains with RT126 pattern were susceptible to metronidazole and three of the six strains were susceptible 
to fluoroquinolones. While the strains with RT126 were detected, C. difficile RT078 was not observed among the 
strains. The RT078 and RT126 or RT078-like are considered as hypervirulent strains. They possess the 39 bp dele-
tion in tcdC gene and produce binary toxin. They have similarity in banding patterns in agarose gel-based PCR 
ribotyping method and can be differentiated with the CE-PCR ribotyping25. Presence and detection of RT126 is 
important, because the severe CDI cases are associated with RT126 or RT078-like clone26. In France, RT078/126 
was the second most prevalent RT resistant to tetracycline27 similar to finding of the present study. It is noteworthy 
that CC4 contained two C. difficile RT126 strains (PC062 and PC096) isolated from the same ward (Medical 2) 
of hospital H4 with close genetic relatedness. Antibiotic resistance pattern was similar in both strains except for 
metronidazole. Considering the date of isolation for both strains (November 2015 and August 2017), it is con-
cluded that these strains have had high durability in the ward of a single hospital. With regard to RT014, it was 
only accounted for 3% of strains in this study, while found as one of the most common RTs in European countries7.
In the present research, resistance to vancomycin was detected (4 strains; MIC = 4–16 mg/L and 16 strains; 
MIC ≥ 256 mg/L). Vancomycin reduced susceptibility has been observed in the last years (MICs ≥ 4 mg/L)10,28. 
Recently, the intermediate-resistance to vancomycin (MIC = 4 mg/L) has been noted in the isolates from var-
ious regions of Europe10. Resistance to vancomycin (MIC ≥ 8 mg/L) was previously observed in other studies 
among the isolates belonging to various RTs including RT027, RT126, RT001, RT072 and RT3568,10. The pres-
ence of vanA gene is associated with the resistance to vancomycin in strains of RT001 and reach a statistical 
significance (P = 0.001). However, none of the strains with RT126 pattern had vanA gene and were resistant 
to vancomycin (Table 2). Noren et al., in Sweden reported three isolates belonging to RT002 with vancomycin 
MICs = 4–8 mg/L in a patient who received vancomycin for treatment of septicaemia of Staphylococcus aureus29. 
In 1988, vancomycin-resistant Enterococcus faecium and Enterococcus faecalis containing vanA resistance locus 
were isolated and reported in England for the first time13. In the current study, PCR sequencing of vanA gene 
confirmed the presence of this gene in 24.2% of the strains (3 vancomycin susceptible strains and 13 vancomycin 
resistant strains). Presence of vanA gene may play a role in the resistance to vancomycin in strains examined 
here, because vanA gene was detected in most of the vancomycin-resistant strains (13/16 strains or 81.2%), even 
though the presence of Tn1546 was not confirmed by vanHAX amplification. It is possible that the expression of 
vanA gene does not always occur in the strains; therefore; that is why the vanA gene was detected in vancomycin 
susceptible strains. Detection of vanA gene in C. difficile was performed by Barkin et al., and it was found in 6.1% 
of strains examined11.
The reduced susceptibility to metronidazole was observed in more than half of the strains (12 strains; 
MIC > 2 mg/L, 1 strain; MIC = 6 mg/L, and 52 strains; MIC ≥ 256 mg/L). A study in England reported reduced 
susceptibility to metronidazole in 24.4% of isolates with RT001 pattern22. In a study conducted by Husain et al., 
the nimA-J genes have not been detected in the metronidazole-resistant phenotypes30. Detection of nimA was 
performed by Barkin et al., and it was found in 47.5% of strains11. Since nimA gene was not observed in any 
strains examined here, probably other mechanisms may contribute to resistance to metronidazole. No nimA gene 
was also found in C. difficile isolates in a study conducted by Plaez et al.31. Recently, the pCD-METRO plasmid 
was detected in metronidazole resistant strains by Boekhoud et al., and suggested as the first metronidazole resist-
ance mechanism that is mediated by plasmid32. The other resistance mechanisms; for examples, mutations within 
germination (cspC) loci, sporulation (spo0A), ferric uptake regulator (fur) and corporphyrinogrn III oxidase gene 
(hemN) could be linked to resistance to metronidazole10 and need to be tested in the future studies.
More than half of the strains (51/65 or 78%) were resistant to ciprofloxacin and 43 among 51 strains (43/51 or 
84%) were also resistant to moxifloxacin (co-resistance), while 8 among 51 strains (8/51 or 16%) were susceptible 
to moxifloxacin Since the fluoroquinolones should be noted for their propensity to induce CDI10, highly-resistant 
strains were expected to be observed. The substitution Thr82 → Ile in GyrA has been reported as a predomi-
nant mechanism of resistance to fluoroquinolones particularly in RT02733. It is because the predominant sub-
stitution in the strains examined here was due to the substitution Thr82 → Val. The substitution Thr82 → Ile 
in GyrA was observed in the fluoroquinolones-resistant strains (PC010, PC048, and PC073) with different RTs 
patterns (RT126, RT038, and RT084) and different isolation sources (outpatients, H9, and H3). In the present 
work, the substitution Thr82 → Val in GyrA was not associated with the resistance to fluoroquinolones, since 
this substitution was found in susceptible strains as well. The substitutions Ser416 → Ala, Ser366 → Ala, and 
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Asp426 → Asn in GyrB were detected in susceptible strains as well as resistant strains in this study, in agreement 
with the previous reported data from Europe33,34. Therefore; these substitutions do not appear to have a key role in 
the resistance to ciprofloxacin and moxifloxacin. It was previously reported that one of the moxifloxacin-resistant 
C. difficile isolates had the substitution Asp426 → Val in GyrB33, while in the present study it was observed in one 
moxifloxacin-susceptible strain (PC134) with RT369 pattern. In contrary to the findings by Huang et al.34, that 
had found the substitution Asp426 → Val in GyrB of tcdA negative/tcdB positive strains, this substitution was 
found in tcdA positive and tcdB positive strain (PC134) in the current study. In this research, it is noted that the 
mutation rate in GyrA was higher than GyrB. This finding was previously reported in 2009 by Huang et al.34. The 
mutations in gyrA gene were observed in most of fluoroquinolones- resistant strains, but this observation was not 
statistically significant (OR = 2.5, P value=0.496 and OR = 8.5, P = 0.129) (Table 2).
In the present study, most C. difficile strains examined were resistant to tetracycline. In RT001 strains, the tetM 
gene was found in most of the tetracycline- resistant strains, but this concordance was not statistically significant 
(OR = 1, P = 0.950) (Table 2). The tetM gene was observed in all strains RT126 which were resistant to tetracy-
cline. The tetM gene is a predominant mechanism of resistance to tetracycline. Here, two strains with RT060 
(PC075 strain with MIC = 0.38 mg/L) and RT039 (PC102 strain with MIC ≥ 32 mg/L) contained Tn5397-like. 
Interestingly, all of the strains with RT126 pattern were resistant to tetracycline and harbored Tn916-like (except 
one strain; PC062). In the tetracycline-resistant strains with no detection of Tn5397-like and Tn916-like, prob-
ably other mechanisms are involved in the emergence of the resistant phenotypes. Spigaglia et al., reported the 
RT012 and RT048 strains carrying tetM and tetW genes35. In a study by Bakker et al., Tn916-like was found in all 
tetracycline-resistant C. difficile strains36.
The hypervirulent strains RT027 and RT078 were not detected in Tehran, although they are more frequently 
found in Europe and USA. Due to lack of data regarding the RTs circulating in the Middle East, the genetic 
pattern of hypervirlent strains is not clearly evident in this geographical region as it is in Europe and USA. To 
reach a clear conclusion, several studies are needed to identify the widespread hypervirluent strains in this area. 
In accordance with the previous study in Tehran, the RT001 and RT126 were dominant. A notable point is that 
the majority of the strains belonging to RT001 were multidrug resistant (MDR). The rate of vancomycin resistant 
strains of C. difficile reached an alarming level. This study, for the first time revealed the subtypes of circulating 
RT001 and RT126 in Iran, and shed light on the genetic relatedness of the predominant RTs using MLVA. MLVA 
could subtype the same RTs in different CCs; RT001 in 4 groups as well as RT126 in 4 groups. This study also 
pointed to the intra-hospital dissemination of the strains belonging to RT001 and RT126 for short and long 
periods, respectively. The most important resistance phenotypes observed in our study was vancomycin-resistant 
phenotypes; however, there is a need to assess the role of other presumed genes.
Materials and methods
4-1- Bacterial isolates. A total of 735 faecal specimens were obtained from hospitalized patients (inpa-
tients) from 5 hospitals in Tehran including H3, H4, H6, H9, H10, and outpatients aged 2 to 95 years old. Other 
faecal specimens were obtained from patients whom their settings were not recorded. All of patients were sus-
pected to CDI and had watery diarrhea and tested for C. difficile at anaerobic bacteriology laboratory (ABL) in 
Tehran, Iran.
After alcohol shock, faecal specimens were cultivated on cycloserine cefoxitin fructose agar (CCFA). For 
anaerobic conditions, the jars were attached to Anoxomat device with a gas mixture of 80% nitrogen, 10% hydro-
gen, and 10% carbon dioxide, and then incubated at 37 °C for 48 hours. Isolates were identified as C. difficile by 
colony morphology, the typical odor of C. difficile, and a positive test of L-prolin aminopeptidase. Total genomic 
DNA was extracted by Chelex® 100 (Sigma, USA) from fresh cultures grown on Brucella agar plates supple-
mented with 5% sheep blood. C. difficile strains were identified by PCR assay using the primer set described by 
Kikuchi et al., for 16S rRNA gene37. C. difficile strains were also screened for tcdA and tcdB genes38,39.
4-2- Antimicrobial susceptibility testing (AST). In vitro susceptibility to vancomycin, metronidazole, 
tetracycline, ciprofloxacin, and moxifloxacin was determined by MIC Test Strips (Liofilchem, Italy) with gradient 
antibiotic range from 0.016 to 256 mg/L for vancomycin, metronidazole, and tetracycline and 0.002 to 32 mg/L 
for ciprofloxacin and moxifloxacin. The medium and the strain for quality control were brucella blood agar and 
C. difficile 630, respectively. The breakpoints 2, 2, 0.25, 4 and 4 mg/L were applied for vancomycin, metronidazole, 
tetracycline, ciprofloxacin, and moxifloxacin, respectively23.
4-3- Detection of antibiotic resistance genes and transposon markers. C. difficile strains were 
examined by PCR for the presence of the antibiotic resistance genes including vanA, nim, tetM, gyrA, and gyrB. 
The vanA and nim genes, with resistance to vancomycin and metronidazole, were detected by amplification of 
1030 bp and 458 bp fragments, respectively using the specific primers as described previously40,41. Also, vanHAX 
fragment was amplified with the primer pairs vanH1-vanX2 described by Yu et al., for detection of Tn154642. 
Using PCR, we examined the presence of tetM gene, responsible for resistance to tetracycline using primers 
TETMd-TETMr43. The isolates were examined for the presence of the int and tndX genes, which encode two 
proteins in the Tn916-like and Tn5397-like family of conjugative transposons, respectively using primer pairs 
INTf-INTr and tndX1- tndX344,45. The genes including gyrA and gyrB genes were amplified with the primers 
gyrA1- gyrA2 and gyrB1- gyrB2, respectively33.
PCR products of vanA, gyrA and gyrB were sent to Macrogen, Inc. company (Seoul, Korea) and sequenced on 
an Applied Biosystems 3730xl DNA Analyzer (CA, USA) using either PCR primer. The sequences were compared 
with other sequences using the Basic Local Alignment Search Tool (BLAST) server of the National Center for 
Biotechnology Information (NCBI).
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4-4- CE-PCR ribotyping. For CE-PCR ribotyping, amplification of the 16S-23S rRNA intergenic spacer 
region was conducted by PCR according to the protocol previously described8. C. difficile strain 630 (RT012) 
was used as a control. After sending the chromatogram files (.fsa format) to two laboratories including National 
Reference Laboratory for Clostridium difficile at University Medical Centre, Leiden and Clostridium difficile 
Ribotyping Network for England and Northern Ireland (CDRN), the RTs were assigned for each C. difficile strain.
4-5- Multiple-locus variable-number tandem-repeat analysis (MLVA) typing. The MLVA assay in 
the present study is based on capillary electrophoresis of the five most polymorphic loci. PCR amplification of the 
five selected C. difficile repeat (CDR) loci was performed in singleplex format in a 20 µl final volume containing 
0.2 unit Taq DNA Polymerase 2x Master Mix (Ampliqon, Denmark) and 0.2 mM concentrations of each primer 
on C. difficile strains with the primer sets of 6-carboxyfluorescein (6Fam)-CDR4F-CDR4R, hexachlorofluorescein 
(Hex)-CDR9F-CDR9R, 6Fam-CDR5F-CDR5R, 6Fam-CDR48F-CDR48R and Hex-CDR49F-CDR49R that were 
published previously by Marsh et al.21,46.
PCR products were analyzed by an Applied Biosystems 3730xl DNA Analyzer (CA, USA) with a LIZ1200 
marker as an internal marker for each sample. The C. difficile 630 strain was included in all MLVA PCR ampli-
fication runs and analyses to act as a control standard. Raw allele data were analyzed using Peak scanner (v1.0, 
Applied Biosystem). Minimum spanning tree (MST) was created using Bionumerics software v7.6 (Applied 
Maths, Belgium) with default settings including two priority rules (locus variants with a weight of 10000 and 
locus variants with weight of 10). When the number of repeats in four out of five loci (tolerance = 1) were the 
same, the strains were considered as clonal complex (CC). Copy numbers at each of the five CDR loci were con-
catenated to generate an MLVA type for each isolate (Supplementary Table File).
Diversity index was calculated for the MLVA loci; Diversity index (DI) = 1-Σ nj (nj-1)/N (N-1) where n = total 
number of alleles of a particular locus and N = the total number of alleles across all loci47.
Ethical approval. The ethics committee of Tehran University of Medical Sciences approved the study. All 
patients have signed the informed consent for giving the faecal specimens for research. Parents/legal guardian 
provided written informed consent for their child under the age of 18 years to participate in this study. All lab-
oratory procedures have been performed in accordance with the guidelines of EUCAST, CLSI, and published 
paper. The metronidazole and vancomycin resistant strains will be send for confirmation to the Reference 
Laboratoy at LUMC.
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